NASDAQ: SABSSab Biotherapeutics Inc Stock
$1.85-0.09 (-4.64%)
Updated May 16, 2025
SABS Price
$1.85
Fair Value Price
$0.31
Market Cap
$17.19M
52 Week Low
$1.00
52 Week High
$5.01
P/E
-0.5x
P/B
0.8x
P/S
33.45x
PEG
N/A
Dividend Yield
N/A
Revenue
$377.84k
Earnings
-$34.28M
Gross Margin
100%
Operating Margin
-8,989.31%
Profit Margin
-9,071.8%
Debt to Equity
0.78
Operating Cash Flow
-$31M
Beta
0.67
Next Earnings
May 19, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SABS Overview
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SABS's potential to beat the market
- SABS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SABS
RankedUnranked of 456
RankedUnranked of 456
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $46.01 | A | |
| $8.19 | A | |
| $63.31 | A |
Be the first to know about important SABS news, forecast changes, insider trades & much more!
SABS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SABS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SABS ($1.85) is overvalued by 496.11% relative to our estimate of its Fair Value price of $0.31 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SABS ($1.85) is not significantly undervalued (496.11%) relative to our estimate of its Fair Value price of $0.31 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SABS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SABS due diligence checks available for Premium users.
Valuation
SABS fair value
Fair Value of SABS stock based on Discounted Cash Flow (DCF)
Price
$1.85
Fair Value
$0.31
Overvalued by
496.11%
SABS ($1.85) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SABS ($1.85) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SABS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SABS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.5x
Industry
-154.88x
Market
25.95x
SABS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.8x
Industry
4.21x
SABS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SABS's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.2M
Profit Margin
0%
SABS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SABS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$38.1M
Liabilities
$16.7M
Debt to equity
0.78
SABS's short-term assets ($16.30M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SABS's short-term assets ($16.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SABS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.8M
Investing
$4.7M
Financing
-$174.0k
SABS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SABS vs Biotech Stocks
Sab Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.